Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ Gold
search
Subscribe
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ Gold
Subscribe
FREE
Home
Oncology
Prof Brian van Tine
Prof Brian van Tine
9 Jul 2024
Oncology
Share:
More great content like this
- straight to your inbox >
Related To This Subject
Oncology
9th
July
Dr Erika Hamilton
Oncology
9th
July
Dr Caroline Michie
More articles
Oncology
11 Sep 2025
FDA Approves IMFINZI Plus Carboplatin and Paclitaxel for Certain Patients With Endometrial Cancer
Oncology
10 Sep 2025
Avelumab 1L Maintenance in aUC: Insights from 5000+ Real-World Patients
Oncology
14
Mins
5 Sep 2025
Sponsored Content: EV+P use in Comorbid Patients with u/mUC
Featured journals
Oncology
September 2025
EMJ Oncology 13 [Supplement 5] 2025
Oncology
September 2025
EMJ Oncology 13 [Supplement 4] 2025
We’ve noticed you’re accessing
from
North/South America.
View
View
